Abstract: The invention relates to peptidic compounds, which peptidic compounds are compounds of formula (I)?, or a pharmaceutically acceptable salt, or solvate, or N-oxide, or stereoisomer thereof: wherein R1; R2; s; t; u; Aa78 and G1 are as defined herein. The peptidic compounds are useful in activating the Nrf2 pathway.

Abstract: A combination which comprises (a) corticosteroid and (b) a dual muscarinic antagonist-?2 adrenergic agonist compound, or any pharmaceutically acceptable salt or solvate thereof.

Abstract: Methods, systems, computer-readable media, and apparatuses for estimating a user's heart rate using a PG signal are presented. In some implementations, the heart rate is estimated by computing a frequency-domain PG, identifying one or more features in the frequency-domain PG, selecting qualified features from the one or more features, and constructing one or more traces. In some implementations, an accelerometer signal can be used for motion cancellation to eliminate traces that are motion artifacts.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a dicarboxylic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.

Abstract: Disclosed are methods and apparatus for transmitting sensor timing correction messages with a host controller. The methods and apparatus determine synchronization messages that are transmitted to a sensor coupled with the host controller via an interface, where the messages indicate a beginning of a synchronization period for synchronizing timing of the host controller and the sensor. Additionally, a delay time message is determined that indicates a time delay between the beginning of the synchronization period and an actual transmission time of the synchronization message. The synchronization message is transmitted with the delay time message in an information message to the sensor, where information message is configured to allow the sensor to correct timing of a sensor timer by accounting for the delay time.

Abstract: Disclosed are methods and apparatus for synchronizing a controller and sensors in a system. A timestamp is provided in a host controller of an interface event on an interface coupled with host controller through detecting a message from a sensor on the interface that identifies the issuance of the interface event caused by the sensor at a first time. In response, the controller issues first and second events on the interface at respective second and third times, while concurrently counting cycles of a clock in the controller after each issuance. The controller also receives a first and second sensor counts representing the internal sensor clock times noted for the first and second events. The controller may then accurately calculate the timestamp of the interface event corresponding to the first time based on both internal controller counts and the sensor counts without needing a timestamp from the sensor directly.

Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a hydroxycarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: Disclosed aspects relate to methods and apparatus for correcting a first sensor clock of a first sensor. The disclosed methods and apparatus effectuate receiving first and seconds signals in a sensor from a processor at known different times related to the timing of the processor clock. Based on the measured time interval between the times of the first and second signals as determined by the sensor, a clock correction factor may be determined in the sensor for correcting the timing of the sensor clock to be synchronized with the processor clock.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: Methods, systems, computer-readable media, and apparatuses for estimating a user's heart rate using a PG signal are presented. In some implementations, the heart rate is estimated by computing a frequency-domain PG, identifying one or more features in the frequency-domain PG, selecting qualified features from the one or more features, and constructing one or more traces. In some implementations, an accelerometer signal can be used for motion cancellation to eliminate traces that are motion artifacts.

Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

Abstract: A combination which comprises (a) corticosteroid and (b) a dual muscarinic antagonist-?2 adrenergic agonist compound, or any pharmaceutically acceptable salt or solvate thereof.